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The Wnt/␤-catenin signaling pathway is a multifunctional network that plays an essential role in embryonic development, organogenesis, and tissue homeostasis (31) . The activation of Wnt signaling inhibits the activity of glycogen synthase kinase-3␤ (GSK-3␤) which induces the accumulation of dephosphorylated ␤-catenin in the cytosol and its translocation into the nucleus (43) . These actions allow for enhanced interaction of ␤-catenin with components of the high mobility group family of transcription factors which activate gene expression (9) . Several models of intrarenal renin-angiotensin system (RAS) overactivation, including obstructive uropathy (44) and renal fibrosis (15, 16, 40) , show dysregulation of Wnt/␤-catenin signaling in which ␤-catenin target genes such as Twist, LEF1, and fibronectin are upregulated in a time-dependent manner (39, 40) . ANG II also exerts profibrotic effects in mesangial cells, podocytes, and proximal tubule epithelial cells in the kidney (1, 51) . The collecting duct cells can also be involved in tubulointerstitial fibrosis (2) and undergo epithelial mesenchymal transition (18) . However, it has not been determined whether AT 1 receptor signaling interacts with the ␤-catenin pathway to induce fibrosis in the collecting ducts. In the present study, we test the hypothesis that the activation of AT 1 receptor stimulates fibronectin and collagen I via activation of the ␤-catenin-dependent signaling pathway in M-1 cortical collecting duct cells.
METHODS
Cell line culture and treatments. M-1 cortical collecting duct cells (American Type Culture Collection; CRL-2038) were grown in DMEM-F12 media supplemented with 10% FBS, 5 M dexamethasone, 1ϫ insulin-transferrin-selenium, and 100 U/ml penicillin/streptomycin in a humid atmosphere of 5% CO 2-95% room air at 37°C. Cells were then treated with ANG II (10 Ϫ7 M) for 16 h. An additional group of cells was treated with either an inhibitor of the Wnt signaling pathway (pyrvinium pamoate; 10 Ϫ9 M) or an AT1 receptor (candesartan; 10 Ϫ7 M) blocker. The dose of pyrvinium pamoate was based on previous studies showing its effectiveness at nanomolar concentrations in reducing ␤ catenin phosphorylation and proliferation in tumor cells (22, 28, 38, 45) . Additionally, it has been shown that pyrivinium pamoate selectively potentiates the casein kinase alpha activity with an EC 50 of 10 nM (45) .
Immunofluorescence in M-1 cells. Subconfluent M-1 cells (50 -60%) cultured in chamber slides (Nalge Nunc, Rochester, NY) were fixed in cold methanol for 20 min, blocked with PBS-Tween (0.1%) plus BSA (3%) for 1 h, and stained with rabbit anti-␤-actin (Cat. no. sc-130657; Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilutions, and detected with Alexa Fluor 488 conjugated to anti-rabbit IgG (Invitrogen, Carlsbad, CA) at 1:1,000 dilution. Samples were counterstained with 4=,6-diamidino-2-phenylindole (Invitrogen). Negative controls were obtained by omission of the specific primary antibody.
Measurements of fibronectin, collagen I, cyclin D1, and c-myc mRNAs by qRT-PCR. Quantitative real-time RT-PCR (qRT-PCR) was performed using the TaqMan PCR system. Total RNA (20 ng) was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA). The following primers and probes used to amplify the genes: Fibronectin: 5=-TGCCGTGGTCCTAACAAATC-3= (sense), 5=-GTGAATGAGTTG-GCGGTGAT-3= (antisense), and 5=-6-FAM-AGGCAGAAAACAG-GTCTCGA (BQH1a-6FAM)-3= (fluorogenic probe); Collagen I: 5=-GAGTACTGGATCGACCCTAA-3= (sense), 5=-GAGTAGGGAA-CACACAGGTC-3= (antisense), and 5=-6FAM-CCATCAAGGTC-TACTGCAACATGG-BHQ1-3= (fluorogenic probe); cyclin D1: 5=-GCTGCAAATGGAACTGCTTC-3= (sense), 5=-GGGTGGGTTG-GAAATGAACT-3= (antisense), and 5=-6-FAM-AGCATGCACA-GACCTTTGTG (BHQ1a-6FAM)-3= (fluorogenic probe); and c-myc: 5=-TCAGTGGTCTTTCCCTAC-3= (sense), 5=-GTGTCTCCTCATG-CAGCACT-3= (antisense), and 5=-6-FAM-TCCTGTACCTCGTC-CGATTC (BHQ1a-6FAM)-3= (fluorogenic probe). Data were normalized against ␤-actin mRNA levels using primer and probe sequences as previously described (11) .
Protein expression of ␣-smooth muscle actin, fibronectin, collagen I, cyclin D1, c-myc, and ␤-catenin. Protein expression levels were quantified after immunoblotting using a 1:1,000 dilution of the following specific antibodies: ␣-smooth muscle actin (␣-SMA; Cat. no. sc 53142 Santa Cruz Biotechnology), fibronectin, collagen I (Cat. no. F3648, SAB4500363; Sigma, St. Louis, MO), activated ␤-catenin (anti-ABC, Cat. no. 05-665; Millipore, Billerica, MA), p-␤-catenin (ser33/37/Thr41; Cat. no. 9561; Cell Signaling Technology, Danvers, MA); and cyclin D1, c-myc, and ␤-actin (Cat. no. sc-717, sc-788, and sc-130657, respectively; Santa Cruz Biotechnology). Primary antibodies were followed by incubation with either donkey anti-rabbit or anti-mouse IgG IRDye 800 CW (Li-cor Biosciences, Lincoln, NE) at a 1:30,000 dilution. Densitometric analyses were performed by normalization against ␤-actin.
Statistics analysis. Each experiment constituted an average of five to six independent observations (each well represented an independent observation). Experiments were performed in at least three different cell passages. Cells were used until passages 10 -12 . Differences between groups were assessed by one-way ANOVA followed by Tukey's test using the GraphPad Prism software v 5.0 (GraphPad Software, San Diego, CA). P Ͻ 0.05 was considered statistically significant. The results shown in plots and texts are expressed as means Ϯ SD.
RESULTS

ANG II induces myofibroblast-like phenotype and ␣-SMA protein levels in M-1 cells.
To evaluate whether ANG II treatment induces epithelial-mesenchymal transition, M-1 cells were treated with ANG II (10 Ϫ7 M). After 48 h, cells were fixed in methanol and staining with ␤-actin antibody to visualize the cell shape using immunofluorescence. Figure 1A shows three representative fields demonstrating that the number of myofibroblast-like cells was augmented after 48 h of ANG II treatment. As a marker of myofibroblast phenotype induction, we quantified the protein levels of ␣-SMA by Western blot. Figure 1B In the presence of candesartan, the effects of ANG II on cyclin D1 and c-myc were completely abolished (Fig. 3, A and  B) . We next evaluated whether ANG II treatment was able to increase ␤-catenin expression, which would explain the induction of cyclin D1 and c-myc. As shown in Fig. 4 ␤-catenin, ANG II also promoted the phosphorylation of ser-9-GSK-3␤ (fold change p-ser-9-GSK-3␤/GSK-3␤ ratio: 3.56 Ϯ 0.47, P Ͻ 0.05). Previous treatment with pyrvinium pamoate suppressed the ANG II-mediated upregulation of ␤-catenin (fold change: 1.23 Ϯ 0.19, P ϭ nonsignificant vs. control) and p-ser-9-GSK-3␤/GSK-3␤ ratio (fold change: 1.58 Ϯ 0.48, P ϭ nonsignificant). Treatment with pyrvinium pamoate in control cells showed nonsignificant changes in the p-ser-9-GSK-3␤/GSK-3␤ ratio; however, we observed a slight, but significant reduction in ␤-catenin expression levels (fold change: 0.78 Ϯ 0.22, P Ͻ 0.05; Fig. 5 ). Phosphorylated ␤-catenin levels were reduced by ANG II treatment, whereas pyrvinium pamoate prevented this effect (Fig. 6) .
DISCUSSION
In the present study, we demonstrate that in mouse collecting duct cells, ANG II via AT 1 receptor induces the expression of fibronectin and collagen I as well as cyclin D1 and c-myc, which are both target genes of the ␤-catenin signaling pathway. Our results indicate that the activation of the AT 1 receptor induces fibrotic factors in the collecting duct cells through the stimulation of ␤-catenin signaling.
Angiotensin II is the major fibrogenic factor in the kidney and most of its effects are related to cell cycle dysregulation (51) . Systemic chronic infusion of ANG II induces the overexpression of fibronectin and collagen I deposition in the kidney (52) . Some of the ANG II-dependent mechanisms involved in the development of CKD involve oxidative stress, intrarenal RAS overactivation, and high blood pressure (11, 21, 46) . Additionally, other factors may contribute to the stimulation of fibrosis, independent of ANG II (15, 16) . The sustained formation of peroxynitrite in rats fed a high-salt diet may induce sulfhydryl oxidation, protein nitration, and lipid peroxidation, which all contribute to kidney injury (8) , as reflected by the glomerular expansion and tubulointerstitial fibrosis. We reported that an excessively high-salt diet, by itself, leads to a marked increase in peroxynitrite formation and predisposes the kidney to greater tubulointerstitial injury when associated with chronic ANG II infusions (23) . High salt also independently stimulates TGF-␤1 (47) and other intracellular signaling pathways leading to an enhanced response to ANG II. In fact, we showed in rats that physiological intrarenal RAS activation in response to a chronic low-salt diet, despite absence of major renal tissue injury, augmented renal tubulointerstial fibrosis (42) .
Although most of the profibrotic effects of ANG II have been reported in mesangial cells, podocytes, and proximal tubule epithelial cells (1, 50) , a direct link between ANG II and (19, 36) . The mechanism by which collecting duct cells undergo extracellular matrix transformation is complex and may involve IGF-induced Akt and GSK-3␤ phosphorylation associated with early disruption of E-cadherin-␤-catenin membrane colocalization with the translocation of E-cadherin to endosomes and ␤-catenin to the nucleus (18) . ␤-Catenin is expressed along the nephron and plays a role in kidney disease (20, 30) . However, there is little evidence about its role in collecting duct cells. Recent studies have suggested that lithium decreases renal medullary GSK-3␤ activity (35) and is associated with nephrotoxicity (33), and changes in cellular composition in the distal nephron (4, 5) . Kidneys from lithium-treated rats show upregulation of p-ser-9GSK-3␤ and proliferating cell nuclear antigen in the cortex and medulla. Lithium is an unspecific activator of the Wnt pathway (34) . Despite its effects on GSK3-␤, lithium also inhibits other enzymes like the inositol monophosphatase, inositol polyphosphate 1-phosphatase, fructose 1,6-bisphosphatase, bisphosphate nucleotidase, adenylate cyclase, and PKC, among others (34) .
Because the dysregulation of the evolutionarily conserved Wnt/␤-catenin signaling system has been involved in the development of fibrotic processes (13, 18) , we further examined whether ANG II induces profibrotic genes via ␤-catenin sig- naling pathway activation. We tested the expression of cyclin D1 and c-myc, both classic target genes of this pathway. Our data agree with previous in vitro studies showing that ANG II upregulates cyclin D1 expression in Chinese hamster ovary cells expressing AT 1 receptor (12). Moreover, Diep et al. (6) showed that in ANG II-infused rats there was an increased cyclin D1 expression in blood vessels. Additionally, in rat vascular smooth muscle cells, ANG II induced the expression of c-myc (29) . Diez et al. (7) showed that inhibition of ACE reduced c-myc levels in smooth muscle cells in spontaneous hypertensive rats. Although the binding of ANG II to the AT 1 receptor exerts most of the pathophysiological effects of ANG II by promoting cell proliferation and inflammation (26) , our data indicate that AT 1 receptor-dependent activation of the ␤-catenin signaling pathway also plays an important role on the stimulation of profibrotic factors in collecting duct cells. Free ␤-catenin is phosphorylated by GSK-3␤ and is rapidly targeted for proteosomal degradation (32) . However, different stimuli can inhibit GSK-3␤ via phosphorylation at the Ser9 site leading to ␤-catenin stabilization (32) . AT 1 receptor is widely expressed along the nephron (14) and its activation leads to PKC activation and calcium accumulation in collecting duct cells (11) . It has been suggested that ␤-catenin stabilization can be induced by the activation of PKC with phorbol esters in T cells (25) . Therefore, we examined whether the effect of ANG II on ␤-catenin signaling trans-activates transcription factors of the TCF/LEF family for the activation of gene expression (43) . Our data suggest that the direct AT 1 receptor-dependent activation of ␤-catenin signaling stimulates ␤-catenin downstream target genes in M-1 cells since candesartan prevented this effect. The inhibition of ␤-catenin signaling by pyrvinium treatment decreases protein and mRNA levels of profibrotic genes and ␤-catenin target genes induced by ANG II. Notably, the expression of cyclin D1 and c-myc, both widely known ␤-catenin target genes implicated in regulating cell proliferation, was correlated with ␤-catenin stabilization. Our results indicated that ANG II treatment increases Ser9-GSK-3␤ phosphorylation leading to the stabilization of ␤-catenin. Interestingly, ANG II also induced the upregulation of total ␤-catenin and decreased its phosphorylation. We confirmed our observations demonstrating that after 48 h, ANG II treatment induces a mesenchymal phenotype demonstrating that the M-1 cells can undergo epithelial mesenchymal transition as previously suggested (18) .
In conclusion, this study demonstrates that ANG II increases ␤-catenin protein levels in a time-dependent manner, whereas cotreatment with pyrvinium pamoate decreases both ␤-catenin and p-ser9-GSK-3␤. Our findings support the concept that in collecting duct cells, ANG II has a stimulatory effect on the ␤-catenin signaling pathway to induce the expression of fibrotic factors. Our data also indicate that AT 1 receptor activation is necessary for induction of the profibrotic factors, fibronectin and collagen I, through a mechanism involving ␤-catenin stabilization in collecting duct cells. These results suggest a role for AT 1 receptor in the development of fibrosis in tubuloepithelial cells of the collecting duct. ␤-catenin and p-ser9-GSK-3␤ while the phosphorylation of ␤-catenin decreases; however, pretreatment with pyrvinium pamoate prevented this effect. *P Ͻ 0.05 vs. control (n ϭ 6).
